MDM S.p.A.   Report issue

For profit Phase 2 Phase 3
Founded: Monza Italy (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
2008
NCT00440921
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

MDM | MDM S.p.A.

Active Ingredients

Drugs in Phase 3 Trials (1)

tizanidine (zanaflex) (1 trial)

Drugs in Phase 2 Trials (1)

choline alphoscerate (1 trial)

Drugs in Other Trials (2)

fasemets (1 trial)

human fibrin (Tisseel) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 3)

Cognitive Dysfunction (Phase 2)

Low Back Pain (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4